previous | next

Graphics

Figure INF-1: AIDS cases among IDUs by country (WHO European Region) and year of diagnosis (1982 to 2003) adjusted for reporting delays

Figure INF-2: AIDS cases by transmission group and year of diagnosis (1987 to 2003) adjusted for reporting delays, EU

Figure INF-3: HIV prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003

Figure INF-4: HIV prevalence among injecting drug users under age 25 – studies with national and subnational coverage, 2002 to 2003

Figure INF-5: HIV prevalence among injecting drug users (injecting less than 2 years) – studies with national and subnational coverage, 2002 to 2003

Figure INF-6: HCV prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003

Figure INF-7: HCV prevalence among injecting drug users under age 25 – studies with national and subnational coverage, 2002 to 2003

Figure INF-8: HCV prevalence among new injecting drug users (injecting less than 2 years) – studies with national and subnational coverage, 2002 to 2003

Figure INF-9: HBV prevalence among injecting drug users (percentage with HbsAg) – studies with national and subnational coverage, 2002 to 2003

Figure INF-10: HBV (antibodies) prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003

Figure INF-11: HIV infections newly diagnosed in injecting drug users in selected EU countries, Russia and Ukraine, by year of report

Figure INF-12: Proportion of notified cases of hepatitis C that are reported as IDU for some EU countries

Figure INF-13: Numbers of notified cases of hepatitis C in IDUs 1992 to 2003, absolute numbers indexed to 100%

Figure INF-14: Notified cases of hepatitis B, proportion of cases reported as IDU

Figure INF-15: Trends in numbers of notified cases of hepatitis B in IDUs, 1992 to 2003, absolute numbers indexed to 100%

Figure INF-16: Trends in HIV seroprevalence among injecting drug users, 1991 to 2003

Figure INF-17: Trends in HCV seroprevalence among injecting drug users, 1997 to 2004

Figure INF-18: Trends in HBV (HBsAg) seroprevalence among IDUs, 1997 to 2003

Figure INF-19: Trends in HBV antibodies seroprevalence among IDUs – trends for some EU countries, 1991 to 2004

Figure INF-20: Prevalence of HIV infection among injecting drug users, 2002 to 2003

Figure INF-21: Prevalence of HCV infection among injecting drug users, 2002 to 2003

Figure INF-22: Prevalence of HBV infection (HBsAg) among injecting drug users, 2002 to 2003

Figure INF-23. Prevalence of HBV infection (antibodies) among injecting drug users, 2002-03

Figure INF-24: Clinically diagnosed AIDS incidence per 100 000 population in Europe

Figure INF-25: Estimated access to highly active anti retroviral treatment (HAART) in WHO European Region, end of 2004

Figure INF-26: Trends in HIV seroprevalence among IDUs under the age of 25

Figure INF-27: Trends in HIV seroprevalence among new IDUs in some EU countries

Figure INF-28: Trends in HCV seroprevalence among IDUs under age 25, 1994 to 2003

Figure INF-29: Trends in HCV seroprevalence among new IDUs, 1994 to 2003